NORCURON (vecuronium bromide) by Merck & Co. is clinical pharmacology vecuronium is a nondepolarizing neuromuscular blocking agent possessing all of the characteristic pharmacological actions of this class of drugs (curariform). First approved in 1984.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
NORCURON (vecuronium bromide) is a nondepolarizing neuromuscular blocking agent used during anesthesia to produce skeletal muscle relaxation and facilitate intubation. It works by competing for cholinergic receptors at the motor end-plate, antagonizing acetylcholine and producing reversible paralysis. The drug is approximately one-third more potent than pancuronium with a shorter duration of action, making it suitable for surgical procedures requiring controlled muscle paralysis.
Product is approaching end-of-life with limited growth opportunities; brand teams may be managing decline or transitioning to newer agents.
CLINICAL PHARMACOLOGY Vecuronium is a nondepolarizing neuromuscular blocking agent possessing all of the characteristic pharmacological actions of this class of drugs (curariform). It acts by competing for cholinergic receptors at the motor end-plate. The antagonism to acetylcholine is inhibited…
Worked on NORCURON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
NORCURON roles are limited in number and primarily focused on maintaining market presence in hospital operating rooms and anesthesia departments rather than driving innovation or growth. Professionals joining this product team should expect operational focus on efficiency, managed care negotiations, and defending market share against generics and newer alternatives.